clinical trial · NCT07434180
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Peter MacCallum Cancer Centre, Australia·phase2·not yet recruiting·n = 20
Cancer of Unknown Primary177Lu-FAP-2286
brief summary
The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).
started
Jun 1, 2026
primary completion
Jun 1, 2030
completion
Jun 1, 2030
last updated
Feb 25, 2026
detailed description
The aim of the Lu-FAP-CUP trial is to assess preliminary efficacy signal of 177Lu-FAP-2286 in CUP patients with 68Ga-FAPI-46 positive disease.
This is a prospective, open label, single site, phase II clinical trial designed to evaluate the safety and efficacy of 177Lu-FAP-2286 monotherapy in CUP patients.
Patients who meet all eligibility criteria will be registered into the trial and receive up to 6 cycles of 177Lu-FAP-2286 monotherapy every 28 days.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol